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AbstrAct
Objectives Cross-sectional studies suggest that around 
6% of men undergo prostate-specific antigen (PSA) testing 
each year in UK general practice (GP). This longitudinal 
study aims to determine the cumulative testing pattern of 
men over a 10-year period and whether this testing can 
be considered equivalent to screening for prostate cancer 
(PCa).
setting, participants and outcome measures Patient-
level data on PSA tests, biopsies and PCa diagnoses were 
obtained from the UK Clinical Practice Research Datalink 
(CPRD) for the years 2002 to 2011. The cumulative risks 
of PSA testing and of being diagnosed with PCa were 
estimated for the 10-year study period. Associations of a 
man’s age, region and index of multiple deprivation with 
the cumulative risk of PSA testing and PCa diagnosis were 
investigated. Rates of biopsy and diagnosis, following 
a high test result, were compared with those from the 
programme of PSA testing in the Prostate Testing for 
Cancer and Treatment (ProtecT) study.
results The 10-year risk of exposure to at least one PSA 
test in men aged 45 to 69 years in UK GP was 39.2% 
(95% CI 39.0 to 39.4%). The age-specific risks ranged 
from 25.2% for men aged 45–49 years to 53.0% for men 
aged 65–69 years (p for trend <0.001). For those with a 
PSA level ≥3, a test in UK GP was less likely to result in a 
biopsy (6%) and/or diagnosis of PCa (15%) compared with 
ProtecT study participants (85% and 34%, respectively).
conclusion A high proportion of men aged 45–69 years 
undergo PSA tests in UK GP: 39% over a 10-year period. 
A high proportion of these tests appear to be for the 
investigation of lower urinary tract symptoms and not 
screening for PCa.
trial registration 
number ISRCTN20141297,NCT02044172.
IntrOductIOn
The UK currently runs three screening 
programmes for breast, bowel and cervical 
cancers. Prostate cancer (PCa) is now the 
most commonly diagnosed cancer in men 
in the UK despite there being no formal 
screening programme.1 Prostate-specific 
antigen (PSA) level can be used as a screening 
test, with prostate biopsy in men with a raised 
PSA level allowing histopathological confir-
mation of the diagnosis of PCa. Despite 
almost 30 years of PSA testing, the balance of 
benefits and harms of the test has not been 
established and, perhaps as a consequence, 
there are varying rates of testing around the 
UK and the world.2 There is evidence that a 
PSA-based screening programme will reduce 
mortality due to PCA3 but with a risk of over 
diagnosis, such that a man diagnosed with 
cancer localised to the prostate would not 
have developed clinical symptoms of the 
disease in his lifetime if left untreated.4 5 
Radical treatment of such men exposes them 
to the risk of treatment-related adverse events 
without the potential to benefit.6 
Current guidance for Primary Care Physi-
cians in the UK, USA and Australia recom-
mends discussing and coming to a shared 
decision about PSA testing,7 with men who 
either raise the issue or warrant consider-
ation of testing, due to a family history of the 
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Research
strengths and limitations of this study
 ► This is the first study in the UK to look at patterns 
of prostate-specific antigen (PSA) testing over a 10-
year period in a cohort of men.
 ► Data on over 430 000 men could be analysed 
from the Clinical Practice Research Database 
and compared with data on 58 500 men from the 
programme of PSA testing and diagnostic biopsy 
in the Prostate Testing for Cancer and Treatment 
(ProtecT) study.
 ► The completeness of some routine data items 
is uncertain; with the recorded diagnoses 
outnumbering the recorded biopsies indicating that 
the latter are under-recorded.
 ► It was not possible to distinguish tests undertaken 
in men with and without symptoms; therefore, the 
proportion of tests prompted by the presentation of 
lower urinary tract symptoms was inferred.
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disease, for example. With such passive advice, variable 
testing rates across GPs are unsurprising. Three cross-sec-
tional studies have been conducted giving an indica-
tion of the PSA testing rates in the UK between 2001 
and 2011. Melia et al, studying 469 159 men aged 45–84 
years, reported an annual rate of 6% over 1999–2002 
for England and Wales, with an annual rate of 2% in the 
absence of symptoms.8 Williams et al, studying 126 716 
men aged 45–89 years and without a prior diagnosis of 
PCa, found that 6.2% of these men received a PSA test 
during 2007.9 This study concluded that testing was more 
prevalent in older men, more southern areas of the UK 
(especially Wales) and areas of lower deprivation. Moss et 
al obtained data from the Clinical Practice Research Data-
link (CPRD) on 650 264 men aged 45–84 years and found 
a testing rate of 8.74 and 9.45 per 100 person-years in 
2010 and 2011, respectively.10 Again, rates increased with 
age and areas of lower deprivation. Of 49 306 men tested 
in 2010 and with at least 9 months of follow-up, 0.2% of 
men with a PSA level <3 ng/mL were diagnosed with PCa 
within 9 months, rising to 14.5% of men with PSA level 
>5 ng/mL. A London-based study of 150 481 men aged 
40 years or older found that 8.2% of men were PSA-tested 
at their general practice (GP) in 12 months from August 
2013 to July 2014.11
When PSA tests are undertaken for screening, men 
with a raised level will be referred for biopsy, with exam-
ination of prostate tissue necessary for the diagnosis of 
PCa. Furthermore, as screen-detected PCa is relatively 
slow to progress, screening is targeted at men in their 
50s and 60s, the balance of risks of short-term treatment 
harms and longer-term survival benefit being less favour-
able for older men as death due to other causes is more 
likely and radical treatments less suitable. Tests which 
are unlikely to be followed up by biopsy, and which are 
undergone by older men, are likely to be guiding the 
treatment of benign hyperplasia of the prostate.12 Guid-
ance for the assessment of lower urinary tract symptoms 
(LUTS), affecting approximately 30% of men over 50s,13 
includes consideration of a PSA when LUTS are sugges-
tive of bladder outlet obstruction secondary to benign 
prostatic enlargement; where PSA >1.4 ng/mL can direct 
drug treatment decisions.14
While estimates of the number of men undergoing 
a PSA test in a 12-month period give an indication of 
how widespread use of the test has become in UK GP, 
a longitudinal perspective is needed to examine how 
the PSA test is being used to manage the risk of PCa in 
individual men. Long-term retrospective cohort studies 
of PSA testing rates have been conducted elsewhere in 
Europe15 16; however, the cumulative risks of PSA testing 
in the UK are yet to be quantified.
The primary objective of this study was to estimate the 
cumulative risk of PSA testing of UK men in primary 
care, without a diagnosis of PCa, over the 10-year period 
1 January 2002 to 31 December 2011. The association 
of testing rates with age, region and index of multiple 
deprivation (IMD) was investigated. The proportion of 
tests resulting in a biopsy and/or diagnosis of PCa was 
compared with the programme of PSA testing, akin to 
screening, in the Prostate Testing for Cancer and Treat-
ment (ProtecT) study17 to gauge whether PSA tests under-
taken in UK GP can be considered as an effective attempt 
at screening.
subjects And methOds
design
We undertook a retrospective cohort study of 450 000 
men using data from the CPRD, a large primary care data-
base.18 The CPRD contains electronic medical records 
for approximately 4.4 million active patients in 674 prac-
tices, representing 6.9% of the UK population. Patients 
in the database were shown to be representative of the 
UK population in terms of age, sex, ethnicity and body 
mass index. However, the data do not include prisoners, 
private patients, some residential homes and the home-
less.19 Practices participating in the CPRD have been 
found to have a greater number of patients compared 
with the national average.20
Data were requested for GP surgeries in all areas 
of UK but excluding London as it is thought that PSA 
testing rates would be markedly different in the capital.11 
We included practices which contributed acceptable 
‘research standard’ data for the observation period, 1 
January 2000 to 31 December 2011.19 Data requested 
from the CPRD included: age, IMD from 2004, region, 
GP practice size, mortality date and cause, occurrence 
of PSA tests and prostate biopsies. PSA test dates before 
2002 were also collected to estimate how many of the men 
had received a test prior to registration. IMD is an area-
based deprivation measure which ranges from 0 to 100 
with higher scores indicating higher levels of deprivation. 
CPRD bases these on the patients’ postcode (English resi-
dents only) and then creates twentiles to ensure conceal-
ment of individuals’ place of residence.
study population
Entry to the cohort commenced on 1 January 2002. 
Person-years for the time before the first PSA test were 
calculated having censored men from the analysis at the 
earliest of: (1) the end of the study period (31 December 
2011), (2) after receiving a PCa diagnosis or (3) death or 
transfer out of the practice. Men aged 45 to 69 years at 
study entry were included (those born between 1933 and 
1957).
Practices thought to be involved with research involving 
practice-wide PSA testing within the eligible age group 
were excluded. For example, the ProtecT study17 was 
recruiting at UK GPs during 2001 to 2009. This exclusion 
was done by calculating the PSA testing rate for the men in 
each practice for all 60 2-month periods within the obser-
vation period and excluding a practice if in any 2-month 
period all the following conditions were satisfied: (1) the 
testing rate was >3.5 SDs higher than the overall practice 
average, (2) more than 10 men were tested and (3) more 
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than 5% of men not previously tested were tested in this 
period.
statistical analysis
The follow-up period for each man was calculated as the 
difference in years between registration start date (on or 
after 1 January 2002) and censoring (defined above). The 
Kaplan-Meier failure function estimated the cumulative 
proportion of men exposed to at least one PSA test and 
diagnosed with PCa over the course of the 10-year period 
for all men. The log-rank test was then used to investigate 
relationships between characteristics of the men and risk 
of undergoing a PSA test. A Cox proportional hazards 
model and Wald test were also used to check that associa-
tions remained, with or without accounting for clustering 
by practice. For men with full 10-year follow-up and no 
diagnosis of PCa (before or during follow-up), logistic 
and ordinal logistic regression were used to explore rela-
tionships between age group and the number of tests 
each man received.
The percentage of men retested within 365 days of 
their first test was explored by age category and PSA level 
for the CPRD data. For this analysis, all men in CPRD who 
had 365 days of follow-up post-PSA test were included; 
as well as those diagnosed within 365 days. Associations 
between age and retesting were investigated using logistic 
regression. Serum PSA levels for both the first and second 
test were used to determine the percentage of men diag-
nosed out of those who were retested, given their first and 
second PSA levels.
Data on men who attended PSA screening as part of the 
ProtecT study17 were used to explore how routine data 
on PSA tests compare with the tests carried out as part of 
a screening intervention. The ProtecT data were divided 
between men with LUTS and no LUTS and compared 
with the CPRD dataset, by age group and further broken 
down by PSA level. LUTS were defined using five ques-
tions from the International Continence Society Male 
Short-Form questionnaire.21 Men were classified as having 
LUTS if any of the following were true: (1) urinating every 
2 hours or more during the day, (2) urinating at least 
twice during the night or (3) suffering ‘sometimes’, ‘most 
of the time’ or ‘all of the time’ from delayed urination, 
rushing to urinate or leaking before reaching the toilet. 
Men diagnosed with PCa before having their first PSA 
test in ProtecT were removed. PSA level was broken down 
into the following categories to ensure adequate numbers 
in each group: PSA <3, 3≤PSA<4, 4≤PSA<6, 6≤PSA<10 and 
PSA ≥10.
As an additional exploratory analysis, the percentage 
of men undergoing prostate biopsy and the percentage 
diagnosed with PCa within 365 days of their PSA test are 
also presented for men in the CPRD dataset and the two 
groups of ProtecT participants (LUTS and no LUTS). 
Comparisons between cohorts, and between risk groups 
within a cohort, were made using logistic and ordinal 
logistic regression. Within CPRD, biopsies and diagnoses 
were detected using medcodes provided by CPRD which 
correspond to Read-codes which are used in GP in the 
UK. Lists used are in online supplementary table 1.
The CPRD group holds ethical approval from a National 
Research Ethics Service Committee for all purely obser-
vational research using anonymised CPRD data. The 
ProtecT trial holds ethics approval from the Trent Multi-
centre Research Ethics Committee (21/06/2001, ref: 
01/4/025).
results
Final cohort
In total, 450 000 men from 578 primary care practices 
across all regions of the UK (excluding London) were 
included in the CPRD data extract. Of these 450 000 men: 
14 were removed due to missing or conflicting data; 303 
were listed as having died before 2002; 2184 had a diag-
nosis of PCa date before 2002 and 369 patients had no 
follow-up. From the remaining 447 130 patients, 12 894 
(3%) men were removed as they were attendees of 19 
practices suspected of participating in research involving 
practice-wide PSA testing. After the removal of these prac-
tices, the final sample was 434 236 men from 558 practices. 
Of these, 161 478 (37%) had the full 10-year follow-up.
risk of PsA testing and Pca diagnosis
The men were followed up for a cohort total of 2 963 
645 person-years (median 8.25 years, IQR 3.83–10.00). 
Between 2002 and 2011 inclusively, 120 697 (28%) men 
received at least one PSA test, and 7538 (2%) men 
received a PCa diagnosis. The cumulative 1-year, 5-year 
and 10-year risks of receiving a PSA test were 5.1% (95% 
CI 5.0% to 5.2%), 21.4% (95% CI 21.3% to 21.5%) 
and 39.2% (95% CI 39.0% to 39.4%), respectively. The 
Kaplan-Meier curve illustrates the cumulative risk of PSA 
testing over the 10-year period, along with the age-specific 
cumulative risks (figure 1A). A similar trend was seen in 
PCa diagnoses (figure 1B). The cumulative 1-year, 5-year 
and 10-year risks of receiving a PCa diagnosis were 0.2% 
(95% CI 0.2% to 0.2%), 1.0% (95% CI 1.0% to 1.1%) and 
2.7% (95% CI 2.7% to 2.8%), respectively.
Table 1 shows the risks by age group, region, IMD quar-
tiles and testing history. The risk of receiving a PSA test for 
men in the lowest age category (45–49 years) was substan-
tially lower than the highest age category (65–69 years), 
with 10-year risks of exposure to PSA testing of 25.2% and 
53.0%, respectively (p<0.001). Likewise, the risk of diag-
nosis was also lower, with 10-year risks of 0.5% and 6.3% 
for age groups 45–49 years and 65–69 years, respectively.
PSA testing and diagnosis risks varied by region 
(p<0.001). The risks of testing and diagnosis were higher 
in more southern areas, especially the South East Coast 
(47.5% and 3.1%, respectively) and Wales (45.0% and 
2.8%, respectively). The lowest risks were found in Scot-
land (23.8% and 2.4%, respectively) and the North East 
(30.5% and 2.3%, respectively). Those living in areas of 
greater deprivation had a lower risk of testing (46.3% vs 
31.9%) and diagnosis (3.2% vs 1.9%); p for trend <0.001.
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Figure 1 (A) Kaplan-Meier failure estimate: cumulative risk over 10 years of receiving a PSA test, by age group, during the 
period 2002 to 2012. (B) Kaplan-Meier failure estimate: cumulative risk over 10 years of receiving a prostate cancer diagnosis, 
by age group, during the period 2002 to 2012. PSA, prostate-specific antigen.
Those who had received a PSA test prior to registration 
were substantially more likely to receive a PSA test and 
diagnosis than those who had not (73.2 vs 37.0 and 5.9 vs 
2.5, respectively); p<0.001.
number of PsA tests
There were 157 586 men with complete 10-year follow-up 
and no PCa. Of these, 57 491 men (36%) underwent at 
least one PSA test. Older age group was strongly related to 
a greater number of tests over 10 years (p<0.001, table 2).
PsA levels and retesting
Data on PSA levels in CPRD were incomplete, but the 
median first PSA result of those tested with a result 
(n=119 175) was 1.23 ng/mL (IQR 0.70–2.60; figure 2). 
If those with a PSA test date but missing level (n=1522, 
1%) had a result of approximately 0, the median PSA 
would be 1.20 ng/mL (IQR 0.70–2.60). Removing the 
lowest age category (45–49) increased the median PSA 
to 1.34 ng/mL (0.70–2.90), n=102 107. For the ProtecT 
men, the median PSA result of those collected (n=58 542) 
was 0.99 ng/mL (IQR 0.60–1.70). 
Of those PSA-tested with a full year’s follow-up after 
their test (aged 50–69 years), 17 757/90 252 (20%) had 
a second test within a year of their first; of which 17 218 
had an initial result (table 3). Undergoing a second PSA 
test within a year of the first test was strongly associated 
with a higher PSA level at the first test (OR per PSA cate-
gory higher 1.85, 95% CI 1.83 to 1.88; p<0.001). Those 
men with a PSA <3 ng/mL were more likely to be retested 
within a year if they were in an older age group (OR per 
age category older 1.04, 95% CI 1.04 to 1.04; p<0.001). 
This trend was reversed for those men with a PSA ≥3 ng/
mL, those in an older age group were less likely to be 
retested within a year than those in a younger age group 
(OR per age category older 0.98, 95% CI 0.97 to 0.98; 
p<0.001).
Older men were also at greater risk of having a 
higher PSA test than those in younger age categories, 
for ProtecT and CPRD data (for the CPRD cohort, OR 
per age group older1.08, 95% CI 1.08 to 1.08; p<0.001). 
On average, those ProtecT participants presenting with 
LUTS appeared to have higher PSA levels than those with 
no LUTS, whereas men in CPRD had the highest PSA 
results (table 3).
subsequent biopsies and diagnoses
From the ProtecT data, 22 200 men were identified as 
having LUTS (based on our definition) at the consul-
tation for their PSA test, and 36 364 men did not have 
LUTS; 22 193 and 36 349, respectively, had a PSA result 
recorded. For men with a PSA level of 3 ng/mL or higher, 
biopsy and diagnosis rates were much higher in ProtecT 
participants than CPRD. This remained true, even when 
those with a high PSA level were confirmed high in a 
further test (online supplementary table S2); further-
more, for men in the CPRD cohort, a lower proportion 
underwent biopsy than were subsequently diagnosed. 
Overall, the odds of diagnosis within a year of a PSA test 
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Figure 2 Distribution of PSA levels on the log scale. PSA, 
prostate-specific antigen.
was three times higher in the ProtecT study compared 
with the CPRD data for those with PSA ≥3 (OR 2.99, 95% 
CI 2.80 to 3.18; p<0.001).
For CPRD, as expected, men with a higher PSA level 
were more likely to be diagnosed (OR per PSA category 
higher 3.52, 95% CI 3.42 to 3.61; p<0.001), as were older 
men (OR per age category higher 1.08, 95% CI 1.07 to 
1.08; p<0.001). For those aged between 50 and 69 years, 
the biopsy rates were <1%, 1%, 5%, 10% and 13% for PSA 
categories PSA <3, 3≤PSA<4, 4≤PSA<6, 6≤PSA<10 and 
PSA ≥10, respectively. The diagnosis rates were <1%, 1%, 
6%, 18% and 45%, respectively.
dIscussIOn
This paper has examined the risk of receiving a PSA test 
over a 10-year period in a large retrospective cohort of 
men aged 45–69 years in the UK (excluding London). 
The 10-year risk of undergoing a PSA test was estimated 
at 39.2%, whereas the 10-year risk of receiving a PCa diag-
nosis was estimated at 2.7%. Higher rates of both testing 
and diagnoses were associated with older age, more south-
erly region of residence, less deprived IMD and a history 
of PSA testing. For all age groups and PSA levels, the 
proportion of men undergoing biopsy and subsequently 
diagnosed with PCa following a PSA test in UK GP is low 
when compared with men in the PSA testing programme 
undertaken as part of the ProtecT trial.17
Overall, the number of men without a prior diagnosis 
of PCa receiving at least one PSA test over 10 years is 
high, especially given the lack of a screening programme 
in the UK. The higher rates of testing in older men are 
consistent with the findings of other studies of UK GP8–10 
although not with the age distribution of men agreeing to 
participate in the ProtecT study, the latter being in close 
agreement with the male population age distribution, 
with the majority of men being younger than 60 years.17 
These findings suggest that interest in PCa screening is 
not concentrated in the older age groups, and that the 
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greater incidence of testing in older men is likely to arise 
due to other diagnostic indications for the PSA test. The 
increase in testing with age could be due to an increase 
in LUTS with age22 or with the GP wanting to rule out the 
possibility of PCa23 despite this rarely being the cause of 
such symptoms.21 24 It is also thought that the PSA level is 
a useful indicator of prostate volume and may inform the 
choice between treatment options for benign prostatic 
hyperplasia and other benign conditions.12 25
The observation of greater testing of men living in more 
affluent areas is consistent with previous studies.8–10 This 
association presumably arises from more affluent men 
being more likely to request a test or through GPs serving 
more affluent areas being more likely to promote the test 
to their male patients. There is some evidence to suggest 
that PCa is more prevalent in areas of lower deprivation26; 
however, the extent to which PSA testing patterns inform 
this is difficult to determine.
Overall, 11% of men with 10 years of follow-up were 
tested three or more times. This varied by age group, 
20% of men aged 65 to 69 years at the outset being tested 
three or more times, compared with 3% of men aged 
45 to 49 years. Two major trials of PCa screening have 
employed repeated PSA testing,27 28 although the associ-
ation with age would not be expected if the programmes 
in those trials were being followed by UK general prac-
titioners, and certainly not a greater number of older 
men undergoing multiple tests.
ProtecT participants with LUTS had slightly higher 
PSA levels on average than those without LUTS. While 
78% of men in UK GP undergoing a PSA test were 
found to have a level below 3 ng/mL, on average, PSA 
levels were higher than seen in the ProtecT study. In 
part, this will be due to the older age profile of men 
in UK GP compared with ProtecT participants, but it is 
also consistent with more tests in GP being undertaken 
to inform a diagnosis of LUTS, as LUTS are associated 
with elevated PSA levels (there is no reason to suppose a 
higher prevalence of non-symptomatic and undiagnosed 
PCa in CPRD or ProtecT GPs). A strong association was 
observed for all age groups between higher PSA levels 
at a first test and the probability of a man undergoing 
a second test within 1 year, indicating that the results of 
the PSA tests did inform clinical management.
The incidence of biopsy and PCa diagnosis in the 
CPRD cohort suggests that a PSA of 4 ng/mL or more 
was being used in UK GP as a trigger for further diag-
nostic investigations. The incidence of biopsy in the 
CPRD cohort is very low, and the fact that there are 
fewer biopsies than PCa diagnoses suggests that either 
many more men were refusing biopsy, perhaps due to 
the full screening process not being discussed at the 
time of PSA testing, or that biopsy is being under-re-
corded in GP data. However, even allowing for a degree 
of under-reporting, only a small minority of men with 
high PSA levels were recorded as having had a biopsy, 
which contrasts with 80% plus of ProtecT men with PSA 
of 3 ng/mL or higher undergoing the investigation. 
Furthermore, the risk of a PCa diagnosis in the CPRD 
cohort is much lower than in comparable men partic-
ipating in the ProtecT study prospective PSA testing 
programme. These findings are again consistent with 
the majority of PSA tests in UK GP being undertaken to 
inform the diagnosis and management of LUTS in older 
men, with no intention of screening for PCa.
strengths And lImItAtIOns
The major strength of this investigation is the use of 
CPRD data which has allowed a large retrospective 
cohort of men to be constructed and followed up for a 
period of up to 10 years. The use of CPRD data is also 
behind the key weakness of this study: the completeness 
of some data items is uncertain, with the recorded diag-
noses outnumbering the recorded biopsies indicating 
that the latter are under-recorded, presumably even 
when cancer is diagnosed.
We did not attempt to distinguish those tests under-
taken in men presenting with and without symptoms, 
and this could be considered a further limitation of our 
study. Screening aims to diagnose a disease before symp-
toms arise. However, PCa rarely results in LUTS and 
sexual symptoms until it is at an advanced stage. For the 
vast majority of men with urinary and sexual symptoms, 
the cause is benign, and in fact, men with an elevated 
PSA are less likely to be diagnosed with PCa if they also 
have LUTS or impaired sexual function.21 29 The pattern 
of PSA testing in the CPRD cohort suggests that many 
PSA tests are being undertaken to inform the diagnosis 
and management of LUTS and knowing which men had 
been PSA-tested because of a presentation with symp-
toms would have lent further support to this hypothesis.
cOnclusIOn
In UK GP, 39.2% of men aged 45 to 69 years and initially 
free of PCa undergo at least one PSA test during a 10-year 
follow-up period (2002 to 2011). However, testing rates 
are higher in the older age groups, and high PSA levels 
are commonly not followed up by a biopsy, required 
for the diagnosis of PCa. Hence, it is likely that a high 
proportion of these tests are related to investigations or 
management of LUTS and other benign conditions and 
cannot be considered as part of an effective (informal) 
effort to screen for PCa.
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